FLOW will be revealed in ~3 weeks. Another preview via Novo Nordisk #T2D #CKD novonordisk.com/content/dam/nn…

On behalf of the faculty of the Birmingham ESEGH Course, we are thrilled to extend an opportunity to our fellow GI trainees. This December, we're offering two intensive days tailored to the blue book and GI curriculum in preparation for the MCQs ESEGH exam in 2025.

The course…

#GUTVideo by Axel Wester Ying Shang @hanneshagstrom et al on

'Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes' via bit.ly/3w7o5y7

Paper: bit.ly/3WgM60k

🚨Next week UK Parliament is holding an important debate on health inequalities in liver disease & liver cancer

⬇️Help ensure that patient voices are heard

✍️Tag/write to your local MP to ask them to speak on 25th April britishlivertrust.org.uk/we-need-your-s…

V excited to join this amazing team as the EASLnews YI representative

Now I'm no AI expert, but that's kind of the point! AI is here to stay & we all need to embrace it. This Taskforce aims to make AI accessible to the wider hepatology community. Lots of exciting things to come

Hot off the press-the HCC-DELTA study 👇

⚠️ Patients with single HCC curatively treated account for 20% of transplants.

⚠️LT can be safely delayed without hampering pre/post-LT outcomes.

⚠️This has potential to redirect spared organs to critical patients EASLnews

Very hard Tom Marjot. Many of my clinical NHS colleagues have 100s of publications, are investigators on several trials, bring in multi-million pound grants and thrive off using research to improve patient care. However, our neighbouring universities do little to recognise this

‼️ Mobile apps are powerful tools to monitor symptoms and engage in treatment for patients with liver disease

✅ Our editorial with Elliot Tapper summarizes the mobile apps in liver disease and offers suggestions for the path forward Hepatology Communications

journals.lww.com/hepcomm/fullte…

April is National Donate Life Month, a time to celebrate donors and encourage donations. View the Liver Transplantation Journal (LTxJournal) curated article collection. journals.lww.com/lt/pages/colle… #LiverTwitter #LiverTransplant Donate Life America

Here is the summary of new eligibility criteria for treatment of #HBV from the new ⁦World Health Organization (WHO)⁩ guidelines. HBV >2000 and ALT >ULN will encompass most of patients in our clinics. IMO patient choice still critical. ⁦Hep B Foundation⁩ ⁦British Liver Trust⁩ ⁦ICE-HBV⁩

Amazing by University Hospitals Birmingham [email protected] liver team to reach 200 recruited at our birmingham site Dr Felicity Williams LiverAHPs Alice Freer @AshHargreaves5 shahida begum [email protected] Birmingham HPB & Liver Transplant Unit NIHR Birmingham Biomedical Research Centre University Hospitals Birmingham Charity truly Incredible patient-focused team!

The FARGO trial for PSC is coming…
Palak Trivedi and Sarah Al-Shakhshir on top form answering questions about FARGO from people with PSC at last night’s Pepperweed Support’s Ask The Expert NIHR Birmingham Biomedical Research Centre LifeArc #LetsBeatPSC

Non-invasive tests are proving to be as good as, if not better than, liver biopsy in predicting patient prognosis for steatotic liver disease. #LiverDisease #MedicalResearch doi: 10.1001/jama.2024.1447

Recent Phase 2 trial results show that daily low-dose #aspirin significantly reduced liver fat in #MASLD patients over 6 months, compared to placebo. A promising step forward, though further study in a larger sample size is necessary to confirm these…

A brilliant and must-read review article on the role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis→jmp.sh/9DSEBrqz Manal Abdelmalek Arun J. Sanyal Novo Nordisk US #MASH #NASH #GLP1 #T2D #diabetes #obesity #livertwitter

This is a great paper from an all ⭐️ team Tracey Simon Khalili Kathleen Corey Rohit Loomba

Looking forward to the day. Hopefully pick up some new imaging techniques and learn about AI tools for our research NIHR Birmingham Biomedical Research Centre

Today, FDA approved a medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. fda.gov/news-events/pr…

It would help if spelt it right .. #resmetirom . Loads of questions to answer. We’ll have to learn from the USA experience. It will be years before this is commissioned in the UK and Europe

Matthew Armstrong 💙 U.S. FDA Phil Newsome EASLnews Ian Rowe The start of a potential revolution in #MASLD therapy. But so many questions remain. Stopping rules? Role of NITs in this? Liver related outcome data? Use with other agents? How/when will it go thru #EMEA approval. Exciting times ahead!!